IRIS Capital Investment
VC Fund
Neuilly-sur-seine, France
IRIS Capital Investment is an independent provider of capital to publicly-listed companies.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 57%
Last updated:
For AI agents: llms.txt
Industries IRIS Capital Investment invests in
Stages IRIS Capital Investment invests in
Countries IRIS Capital Investment invests in
Round sizes
Round size
- Series A
- $2.8M–$5.8M
- Post-IPO Equity
- $3.8M–$11M
Investment Focus
Industry
- Biotechnology 2 (29%)
- Pharmaceutical 2 (29%)
- Legal 1 (14%)
- FinTech 1 (14%)
- Cannabis 1 (14%)
Stage
- Series A 2 (29%)
- Post-IPO Equity 2 (29%)
- Post-IPO Debt 1 (14%)
- Venture - Series Unknown 1 (14%)
Country
- France 4 (57%)
- Germany 1 (14%)
- South Korea 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| SynBiotic unlocks the power of cannabinoids to heal various diseases. They are consolidating the muscular player under one roof to make cannabinoids accessible. They treat chronic pain, stress, and sleep issues that affect health and well-being. | Post-IPO Debt / Apr 17, 2025 | ||
| MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. The company standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. The company servestwo primary markets: drug development and patient care. MEDIAN Technologies has a strategic partnership with a contract research organization to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market. MEDIAN Technologies was founded in 2002 and is based in Sophia-Antipolis, France. | $10.5M / Post-IPO Equity / Jan 24, 2025 | ||
| Poxel is a dynamic biopharmaceutical company developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono, a global leader in the field of metabolic disorders at that time.They believe that targeting cellular energyregulation pathways for the treatment of metabolic diseases, including type 2 diabetes is of critical importance as disbalances are at the root of those diseases. All three of their clinical stage pipeline programs address significant targets in the energy metabolism pathways. Imeglimin, their lead program, targets mitochondrial dysfunction, mitochondria being the power station of the cell, PXL770 activates the adenosine monophosphate-activated protein kinase (AMPK), an important energy sensor, and PXL065 (DRX-065) inhibits the mitochondrial pyruvate carrier (MPC). | $3.8M / Post-IPO Equity / Mar 23, 2023 | ||
| Poxel is a dynamic biopharmaceutical company developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono, a global leader in the field of metabolic disorders at that time.They believe that targeting cellular energyregulation pathways for the treatment of metabolic diseases, including type 2 diabetes is of critical importance as disbalances are at the root of those diseases. All three of their clinical stage pipeline programs address significant targets in the energy metabolism pathways. Imeglimin, their lead program, targets mitochondrial dysfunction, mitochondria being the power station of the cell, PXL770 activates the adenosine monophosphate-activated protein kinase (AMPK), an important energy sensor, and PXL065 (DRX-065) inhibits the mitochondrial pyruvate carrier (MPC). | $6.1M / Post-IPO Equity / Aug 08, 2022 | ||
| Amicus Lex is a provider of legal and professional services. | $2.8M / Series A / Apr 08, 2022 | ||
| YouScribe is the French community platform for sharing and selling digital publications. | $5.7M / Venture - Series Unknown / Feb 11, 2022 | ||
| Youdge is a digital neo-broker with a aim to make the consumer credit market clear and accessible. | $5.8M / Series A / Oct 29, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does IRIS Capital Investment invest in?
IRIS Capital Investment invests primarily in Biotechnology, Pharmaceutical and Legal startups, most often at Series A and Post-IPO Equity stage. Most of the 7 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does IRIS Capital Investment invest in?
IRIS Capital Investment typically joins rounds of $2.8M–$5.8M at Series A and $3.8M–$11M at Post-IPO Equity. These are whole funding-round sizes, not IRIS Capital Investment's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds IRIS Capital Investment took part in.
When did IRIS Capital Investment last invest?
The most recent investment recorded for IRIS Capital Investment closed in Apr 2025. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
